Seres therapeutics announces receipt of $125 million milestone from nestlÉ health science following fda approval of vowst™

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced that the company has received a $125 million milestone payment from nestlÉ health science related to the u.s. food and drug administration approval of vowst™ (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of c. difficile infection (cdi) in adults following antibiotic treatment for recurrent cdi. th.
MCRB Ratings Summary
MCRB Quant Ranking